PrefHer: finally addressing the preferences of her, too
- PMID: 23965224
- DOI: 10.1016/S1470-2045(13)70389-9
PrefHer: finally addressing the preferences of her, too
Comment on
-
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19. Lancet Oncol. 2013. PMID: 23965225 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
